<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute asthma exacerbations in children younger than 12 years: Emergency department management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute asthma exacerbations in children younger than 12 years: Emergency department management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute asthma exacerbations in children younger than 12 years: Emergency department management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Scarfone, MD, FAAP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Redding, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen J Teach, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment (beta-agonist therapy and oral glucocorticoids) of acute asthma exacerbations is sometimes provided in the primary care setting or even at home [
         <a href="#rid1">
          1
         </a>
         ]. However, children with moderate-to-severe exacerbations require close observation for clinical deterioration, frequent treatments, and repeated evaluation. Thus, most children with moderate or severe asthma exacerbations should be managed in an emergency department (ED) setting. The general approach to treatment of an acute asthma exacerbation includes administration of inhaled bronchodilators (eg,
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         ), as well as systemic glucocorticoids in most patients.
        </p>
        <p>
         The approach to ED management of the child with an acute asthma exacerbation is presented here. Management of acute asthma exacerbations in the home, office/outpatient clinic, and inpatient/intensive care unit (ICU) settings are discussed in detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Rescue medications for acute symptoms are also reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"
         </a>
         .)
        </p>
        <p>
         The management of acute asthma exacerbations in adolescents and adults is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/528.html" rel="external">
          "Acute exacerbations of asthma in adults: Home and office management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of therapy for an acute asthma exacerbation include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid reversal of airflow obstruction (see
         <a class="local">
          'Initial treatment'
         </a>
         below and
         <a class="local">
          'Management of bronchospasm'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction of hypoxemia and/or severe hypercapnia, if present (see
         <a class="local">
          'Management of hypoxemia and hypercapnia'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction of the likelihood of hospitalization and recurrence after discharge (see
         <a class="local">
          'Management of inflammation'
         </a>
         below and
         <a class="local">
          'Discharge medications'
         </a>
         below and
         <a class="local">
          'Discharge education'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2462144229">
         <span class="h1">
          ASSESSMENT OF SEVERITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The severity of an asthma exacerbation is primarily determined by assessment of clinical findings, occasionally supplemented by objective tests  (
         <a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild
         </strong>
         – A mild exacerbation is characterized by normal alertness, slight tachypnea, expiratory wheezing only, a mildly prolonged expiratory phase (inspiratory-to-expiratory ratio of 1:1 rather than the normal 2:1), minimal accessory muscle use, and an oxygen saturation of &gt;95 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate
         </strong>
         – A moderate exacerbation is characterized by normal alertness, tachypnea, wheezing throughout expiration with or without inspiratory wheezing, an inspiratory-to-expiratory ratio of approximately 1:2, significant use of accessory muscles, and an oxygen saturation that is typically 92 to 95 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         – A severe exacerbation is characterized by inability to repeat a short phrase, extreme tachypnea, inspiratory and expiratory wheezing, an inspiratory-to-expiratory ratio exceeding 1:2, very poor aeration, significant use of accessory muscles, and an oxygen saturation that is typically &lt;92 percent. Signs of impending respiratory failure include cyanosis, inability to maintain respiratory effort (respiratory rate may be inappropriately normal to low), depressed mental status (lethargy or agitation), pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) &lt;90 percent, and respiratory acidosis (elevated partial pressure of carbon dioxide [pCO
         <sub>
          2
         </sub>
         ] noted on venous, arterial, or capillary blood gas sample).
        </p>
        <p>
        </p>
        <p>
         There are also several ordinal scales available for the assessment of the initial severity of the exacerbation and level of treatment needed. We use the Pulmonary Index Score (PIS)  (
         <a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">
          table 2
         </a>
         ), with a PIS 1 to 6 = mild, PIS 7 to 11 = moderate, or PIS ≥12 = severe [
         <a href="#rid2">
          2
         </a>
         ]. An alternative scale is the Pediatric Respiratory Assessment Measure (PRAM)  (
         <a class="graphic graphic_table graphicRef91731" href="/z/d/graphic/91731.html" rel="external">
          table 3
         </a>
         ). Assessment of the severity of an acute asthma exacerbation, including review of other available scores, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Assessment of exacerbation severity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4001673023">
         <span class="h1">
          ELEMENTS OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of an acute asthma exacerbation in the ED includes both bronchodilators to address acute bronchospasm  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         ) and, in most patients, systemic glucocorticoids to address underlying airway inflammation  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). Supportive care for children with acute asthma exacerbations includes administration of supplemental oxygen and fluids to make up for evaporative losses (oral preferred if patient is able) as necessary.
        </p>
        <p class="headingAnchor" id="H3020883508">
         <span class="h2">
          Management of hypoxemia and hypercapnia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with moderate-to-severe acute asthma exacerbations have hypoxemia as a result of ventilation-perfusion (V/Q) mismatch, although, in most patients, the hypoxemia is mild and does not require treatment with supplemental oxygen. Beta-agonists may worsen this mismatch by causing pulmonary vasodilation in areas of the lung that are poorly ventilated, especially among this sickest subset of children. Hypoxemia is alleviated by administration of supplemental humidified oxygen as needed to maintain an oxygen saturation of ≥92 percent [
         <a href="#rid3">
          3
         </a>
         ]. All nebulized medications should also be delivered with oxygen, generally at a flow rate of 6 to 8 L/min. Hypercapnia usually improves with reversal of airflow obstruction. (See
         <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">
          "Continuous oxygen delivery systems for the acute care of infants, children, and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1309213210">
         <span class="h2">
          Management of bronchospasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional bronchodilators used in children with moderate or severe asthma may include intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         and parenteral beta-agonists such as
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3780124380">
         <span class="h3">
          Inhaled short-acting beta-2 agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled short-acting beta-2 agonists (beta-agonists or SABAs), particularly
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (salbutamol), are the standard emergent treatment for acute asthma exacerbations in all patients based upon adult data, a few early trials in children, and many ensuing years of clinical use [
         <a href="#rid1">
          1,4
         </a>
         ]. Two such small trials in children in the early 1980s demonstrated that nebulized albuterol was similar in efficacy to subcutaneous
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         with regard to need for repeat treatment during the initial ED visit, admission on initial visit, return to the ED after discharge, admission on return visit, clinical score, vital signs, and pulmonary function measures but was less likely to cause adverse effects [
         <a href="#rid5">
          5,6
         </a>
         ]. Subsequent studies have focused on the dosing and route of administration for SABAs. Albuterol has never been compared with placebo. (See
         <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">
          "Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Inhaled beta-agonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Use in acute exacerbations of asthma'
         </a>
         .)
        </p>
        <p>
         SABAs are administered by intermittent nebulization, continuous nebulization, or metered-dose inhaler with a valved holding chamber (MDI-VHC) or spacer (MDI-S)  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         ).
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          Albuterol
         </a>
         (salbutamol) is the SABA used for most patients. The choice of drug and delivery systems are discussed in detail separately and are reviewed briefly here (see
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">
          "Delivery of inhaled medication in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">
          "Use of medication nebulizers in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Racemic
         </strong>
         <strong>
          albuterol
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          levalbuterol
         </strong>
         – Racemic
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         is an equal mixture of two mirror-imaged enantiomers: R-albuterol, the active bronchodilator, and S-albuterol, a possible weak bronchoconstrictor.
         <a class="drug drug_pediatric" data-topicid="12546" href="/z/d/drug information/12546.html" rel="external">
          Levalbuterol
         </a>
         is pure R-albuterol. In theory, pure active R-albuterol would be more effective than racemic albuterol because there is no bronchoconstricting effect from the S-isomer. However, studies of levalbuterol for acute asthma in children have had conflicting results, and, overall, levalbuterol appears to have no clinically significant advantage over racemic albuterol [
         <a href="#rid7">
          7-10
         </a>
         ]. Thus, we use racemic albuterol rather than levalbuterol for children with acute asthma exacerbations, unless the patient has a known history of adverse effects from albuterol. Use of levalbuterol is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Levalbuterol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nebulizer versus inhaler
         </strong>
         – Clinical trials and meta-analyses indicate that the administration of SABAs via MDI-VHC/S (eg, 4 to 12 puffs of
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         ) is at least as effective and possibly superior to delivery of medication by small-volume nebulizer (SVN) in reversing bronchospasm in children of all ages and with a wide range of illness severity [
         <a href="#rid1">
          1,11-13
         </a>
         ]. Thus, the choice of one over the other for intermittent administration of SABAs mainly depends upon the frequency of dosing required. Continuous delivery of the first three doses of albuterol via SVN in the first hour after ED arrival helps to ensure compliance with national treatment guidelines. Additional advantages of SVN delivery compared with MDI-VHC/S include the ability to simultaneously deliver humidified oxygen and
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         bromide and to passively administer drug therapy to a child in respiratory distress. Thus, many ED clinicians choose to treat moderately to severely ill patients with albuterol delivered via SVN. However, when using SVNs, up to 90 percent of drug remains in the machine or is lost to the atmosphere [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'pMDI or nebulizer?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'Spacers and holding chambers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermittent versus continuous delivery
         </strong>
         – Studies comparing continuous versus intermittent nebulized delivery of beta-agonists have found similar outcomes and side effect profiles with both methods [
         <a href="#rid15">
          15-20
         </a>
         ]. We prefer continuous therapy over intermittently nebulized or MDI-VHC/S therapy for children with moderate-to-severe exacerbations. Continuous nebulizer therapy is less labor intensive than intermittent nebulizer therapy, resulting in reduced respiratory therapy costs. In addition, it ensures that the goal of three treatments within the first hour of care for moderately ill children is met. However, young children may not tolerate wearing a facemask for long periods of time. (See
         <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">
          "Use of medication nebulizers in children", section on 'Continuous nebulization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">
          "Delivery of inhaled medication in children", section on 'Patient technique, acceptance, and preference'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Dosing of
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         depends upon route of administration and the severity of the asthma exacerbation  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         ) (see
         <a class="local">
          'Mild exacerbation'
         </a>
         below and
         <a class="local">
          'Moderate exacerbation'
         </a>
         below and
         <a class="local">
          'Severe exacerbation'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Albuterol
         </strong>
         <strong>
          via MDI-VHC/S
         </strong>
         – Optimal dosing for
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         administered by MDI-VHC/S is not well established, and protocols used vary by institution. The 2007 National Asthma Education and Prevention Program (NAEPP) guidelines state that "equivalent bronchodilation can be achieved either by high doses (4 to 12 puffs) of a SABA by MDI with a VHC or by nebulizer"; they suggest a dose of four to eight puffs [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One strategy is to administer one-quarter to one-third puff/kg (22.5 to 30 microgram/kg) with a minimum of four puffs (360 micrograms) and a maximum of eight puffs (720 microgram). Thus, proportionately greater doses are provided for young children weighing less than 20 to 30 kg (44 to 66 pounds), who are the least efficient users.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another strategy is to use a dosing schedule, stratified by weight, as with continuous
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         nebulization:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh 5 to 10 kg, the dose is four puffs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh 10 to 20 kg, the dose is six puffs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh &gt;20 kg, the dose is eight puffs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose can be repeated up to every 20 minutes for three doses, then every one to four hours as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         To maximize drug delivery, a VHC (preferred) or a spacer should be employed by all patients, and infants and young children should use such a device with a facemask, low dead space, and a low-resistance valve. Mouthpieces are preferable to facemasks for older children to avoid nasal filtering of drug, which may reduce lung deposition. Children should take a slow and deep breath at the same time that the MDI canister is depressed. The breath should be held for a count of five. For young children who are unable to breath-hold, the facemask should be held in place for five to six breaths for inhalation of all of the medication. (See
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'Spacer devices'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermittent
         </strong>
         <strong>
          albuterol
         </strong>
         <strong>
          nebulization
         </strong>
         – The standard dose for nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         is 0.15 mg/kg (minimum 2.5 mg; maximum 5 mg) [
         <a href="#rid1">
          1,21
         </a>
         ]. Nebulized albuterol can be administered every 20 minutes for three doses [
         <a href="#rid1">
          1
         </a>
         ]. Beyond that, frequency of therapy may be limited by side effects, such as tachycardia, hypertension, or tremors. Patients who have shown little or no improvement after three doses and who are not experiencing significant adverse effects may be treated every 30 to 45 minutes or switched to continuous therapy. Blow-by techniques for aerosol delivery, rather than using a mask or mouthpiece, should be avoided because they significantly decrease the inspired dose, limiting treatment efficacy. (See
         <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">
          "Delivery of inhaled medication in children", section on 'Special considerations in infants and young children'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug delivery is maximized by having a total solution volume of 3 to 4 mL and an oxygen flow rate of 6 to 8 L/min [
         <a href="#rid22">
          22-25
         </a>
         ], tapping the sides of the reservoir to renebulize droplets, and having older children use a mouthpiece to avoid nasal deposition of drug  (
         <a class="graphic graphic_picture graphicRef66857" href="/z/d/graphic/66857.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continuous
         </strong>
         <strong>
          albuterol
         </strong>
         <strong>
          nebulization
         </strong>
         – The optimal dose for continuous
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         nebulization therapy has not been determined, and protocols used vary by institution. One dosing schedule, stratified by weight, is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh 5 to 10 kg, the dose is 5 to 7.5 mg/hour
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh 10 to 20 kg, the dose is 10 to 12.5 mg/hour
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who weigh &gt;20 kg, the dose is 15 to 20 mg/hour
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1749001147">
         <span class="h3">
          Ipratropium bromide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          Ipratropium
         </a>
         bromide is an inexpensive and safe anticholinergic agent that provides bronchodilation through smooth muscle relaxation [
         <a href="#rid26">
          26
         </a>
         ]. We recommend treating children with a moderate-to-severe asthma exacerbation with ipratropium bromide in addition to a beta-agonist. In randomized trials, systematic reviews, and meta-analyses [
         <a href="#rid27">
          27-31
         </a>
         ], treatment with two to three doses of inhaled ipratropium combined with an inhaled beta-agonist was shown to reduce hospital admissions and improve lung function in children, most with moderate-to-severe asthma exacerbations, compared with an inhaled beta-agonist alone. In a 2013 systematic review, combination therapy was found to reduce the risk of hospitalization (relative risk [RR] 0.73, 95% CI 0.63-0.85, 15 studies, 2497 children), with 23 out of 100 children who received only beta-agonists hospitalized compared with 17 out of 100 who were treated with combination therapy [
         <a href="#rid31">
          31
         </a>
         ]. Thus, 16 children (95% CI 12-29) with an asthma exacerbation of any severity would need to be treated with combination therapy rather than inhaled beta-agonists alone to avoid one hospital admission. The incidence of nausea and tremor was lower in the combination therapy group, but no difference was seen in the rate of vomiting.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          Ipratropium
         </a>
         can be administered via SVN or MDI-VHC/S  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). We prefer the nebulized form (250 micrograms per dose for children who weigh &lt;20 kg; 500 micrograms per dose for children who weigh ≥20 kg). We administer ipratropium bromide with each of the first three
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         treatments [
         <a href="#rid27">
          27
         </a>
         ]. Alternatively, ipratropium may be administered with the second and third treatments [
         <a href="#rid28">
          28
         </a>
         ]. If administered by MDI-VHC/S, the NAEPP guidelines recommend a dose of four to eight puffs (each puff is 18 micrograms) [
         <a href="#rid1">
          1
         </a>
         ]. The NAEPP guidelines also comment that the MDI dose is low and has not been studied in asthma exacerbations.
        </p>
        <p class="headingAnchor" id="H771748284">
         <span class="h3">
          Magnesium sulfate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Magnesium is inexpensive, has minimal adverse effects at the doses indicated, and is widely available. We suggest using intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         in children over four years of age with severe asthma exacerbations and in children over four years of age with moderate asthma exacerbations who have not responded to initial treatment with beta-agonists,
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         bromide, and systemic glucocorticoids. Magnesium sulfate administered intravenously causes relaxation of bronchial smooth muscle, and there is accumulating evidence of its benefits in adults and children with severe asthma [
         <a href="#rid32">
          32,33
         </a>
         ]. A meta-analysis of five studies (182 children) found that magnesium sulfate was effective in preventing hospitalization in children with moderate-to-severe acute asthma when added to bronchodilators and glucocorticoids (absolute risk reduction 0.26, 95% CI 0.12-0.39) [
         <a href="#rid34">
          34
         </a>
         ]. Four children would need to be treated to avoid one hospitalization (95% CI 3-8). Two other systematic reviews and meta-analyses assessed the same five studies and found that the use of magnesium was also associated with significant improvements in pulmonary function tests [
         <a href="#rid35">
          35,36
         </a>
         ]. A subsequent meta-analysis that included six trials was consistent with previous findings [
         <a href="#rid37">
          37
         </a>
         ]. However, a randomized trial of intravenous magnesium sulfate (40 mg/kg) or placebo in 61 children aged six months to four years with acute, severe virus-induced wheezing unresponsive to initial treatment with short-acting bronchodilators in the emergency department found no difference between the two groups in the change in respiratory distress scores from baseline to six hours after treatment [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The NAEPP guidelines suggest 25 to 75 mg/kg (maximum 2 grams) intravenously for severe exacerbations unresponsive to initial treatments after one hour and as add-on therapy for life-threatening exacerbations  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Given its relative safety and the critical importance of early effective treatment, in our practice, we use a dose of 50 mg/kg (maximum 2 grams), given intravenously and administered over 20 minutes. A fluid bolus may be administered to prevent clinically significant hypotension, a rare side effect of magnesium infusion. Magnesium infusion is relatively contraindicated in kidney failure. We do not advocate the use of nebulized
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         , due to lack of demonstrated clinically important benefits in randomized trials [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1597520013">
         <span class="h3">
          Parenteral beta-agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subcutaneous and intramuscular beta-agonists (eg,
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         ) are reserved for children with a severe asthma exacerbation who often have poor inspiratory flow (eg, markedly decreased breath sounds) and/or cannot cooperate with nebulized therapy due to agitation. Additionally, intravenous terbutaline may be used in children with a severe asthma exacerbation who have not responded to initial therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subcutaneous or intramuscular
         </strong>
         <strong>
          epinephrine
         </strong>
         <strong>
          or
         </strong>
         <strong>
          terbutaline
         </strong>
         – Typically, subcutaneous or intramuscular therapy is given within minutes of arrival to a severely ill patient who is aerating poorly, concurrent with starting
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         therapy and obtaining intravenous access. While
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         is more beta-2-selective at lower doses than
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         , terbutaline may lower blood pressure, whereas epinephrine can increase cardiac output and raise blood pressure. In addition, epinephrine is also suitable for anaphylaxis, which can have a similar presentation to a severe asthma attack. In a sick patient, the preferred medication is the one most readily available, which is epinephrine (in the form of autoinjectable epinephrine devices for intramuscular administration) in most cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Early studies showed that inhaled beta-agonists were as efficacious as subcutaneous or intramuscular
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         [
         <a href="#rid5">
          5,6
         </a>
         ]. However, inhaled beta-agonists are poorly delivered in severely ill children with markedly diminished aeration. Theoretically then, in this setting, the rapid subcutaneous or intramuscular administration of beta-agonists (epinephrine or
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         ) may be superior to inhaled beta-agonists. Another subgroup who may benefit from this mode of therapy is anxious, young children who are uncooperative with and have suboptimal response to initial aerosolized therapy. The intramuscular route may provide for more rapid drug absorption compared with the subcutaneous route, although direct comparisons are lacking.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of intramuscular or subcutaneous
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         for bronchodilation is 0.01 mg/kg (0.01 mL/kg a 1 mg/mL solution), with a maximum dose of 0.4 mL (0.4 mg)  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). The dose of subcutaneous or intramuscular
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         for bronchodilation is 0.01 mg/kg/dose (0.01 mL/kg of a 1 mg/mL solution), with a maximum dose of 0.4 mg (0.4 mL). The dose may be repeated every 20 minutes for three doses unless significant side effects (eg, extreme hypertension, persistent emesis) develop, although most patients are switched to an intravenous medication (eg,
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         , terbutaline) if they do not respond after the second dose of subcutaneous or intramuscular terbutaline or epinephrine. The dosing interval may be decreased to 5 to 10 minutes for children who continue with severe respiratory distress; autoinjectable epinephrine may be used for this purpose to avoid a delay in drawing up the medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous
         </strong>
         <strong>
          terbutaline
         </strong>
         – Severely ill patients who are poorly responsive to conventional therapy may be treated with a combination of intravenous beta-agonists and inhaled beta-agonists, although additional studies are needed to clarify the role of intravenous beta-agonists. A systematic review of studies published through September 2012 [
         <a href="#rid40">
          40
         </a>
         ] found only two randomized trials that met inclusion criteria [
         <a href="#rid41">
          41,42
         </a>
         ]. Limited evidence from these two trials suggests that there is shorter recovery time and improved pulmonary index scores (PIS) with the addition of intravenous beta-agonists in children poorly responsive to conventional interventions (including inhaled beta-agonists and
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         , systemic glucocorticoids, and
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         ). Although at least one pediatrics study found no significant adverse effects with continuous intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         , the possible benefit needs to be weighed against increased side effects associated with this therapy, including dysrhythmias, hypertension, and myocardial ischemia [
         <a href="#rid43">
          43,44
         </a>
         ]. Thus, there is no role for using intravenous beta-agonists as
         <strong>
          initial
         </strong>
         therapy, even for severely ill children. Alternative treatment options include noninvasive positive pressure ventilation (NPPV) and high-flow nasal cannula. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'Preintubation therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing for intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         in the ED setting is as follows: 10 micrograms/kg bolus over 10 minutes, followed by 0.3 to 0.5 micrograms/kg/minute; every 30 minutes the infusion may be increased by 0.5 micrograms/kg/minute to a maximum of 3 micrograms/kg/minute. Use of higher doses in the intensive care unit (ICU) setting have been described (up to 6 to 10 micrograms/kg/minute). However, in clinical practice, the maximum dose is often limited to 2 to 3 micrograms/kg/minute because of drug toxicities (eg, troponin leak, electrocardiogram changes). (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1524282899">
         <span class="h2">
          Management of inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The other primary treatment for acute asthma exacerbations in the ED is systemic glucocorticoids.
        </p>
        <p class="headingAnchor" id="H412281324">
         <span class="h3">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids are a well-established asthma therapy and are indicated for all children who present to the ED with a moderate-to-severe acute asthma exacerbation. Most children with mild exacerbations are also treated with systemic glucocorticoids, although it is reasonable to omit this treatment in children who have not received beta-agonist therapy within a few hours of presenting for medical care and who respond promptly to a single
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         treatment in the ED. Systemic glucocorticoids have been used for the treatment of acute asthma exacerbations for over 60 years [
         <a href="#rid45">
          45
         </a>
         ]. The anti-inflammatory action of glucocorticoids effectively reduces the airway edema and secretions associated with acute asthma exacerbations, and their effects may be noted within two to four hours of administration [
         <a href="#rid2">
          2,46
         </a>
         ]. Treatment of moderate-to-severe exacerbations with systemic glucocorticoids in the ED is associated with a decreased rate of hospitalization in placebo-controlled trials (RR 0.58 [95% CI 0.37-0.92] in an analysis of two trials in preschool children, for example) [
         <a href="#rid2">
          2,47
         </a>
         ], and admission rates are similar in children whether they are given oral or intravenous glucocorticoids [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         When indicated, we recommend administering systemic glucocorticoids as soon as possible after arrival in the ED. Oral administration is suitable and preferred for most patients.
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          Dexamethasone
         </a>
         has become the oral glucocorticoid of choice to treat children with acute asthma because of its prolonged half-life and similar efficacy compared with
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid49">
          49,50
         </a>
         ]. The dosing of systemic glucocorticoids is reviewed in the table  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). The NAEPP guidelines suggest that oral administration of glucocorticoids is preferred to intravenous administration because oral administration is less invasive and the effects are equivalent [
         <a href="#rid1">
          1
         </a>
         ]. Intramuscular administration of glucocorticoids (eg, dexamethasone) may be warranted in patients who vomit orally administered glucocorticoids yet do not require an intravenous line for other purposes [
         <a href="#rid51">
          51-53
         </a>
         ].
        </p>
        <p>
         The benefit of early administration (within one hour) of systemic glucocorticoids versus placebo in patients presenting to the ED with acute asthma exacerbation was evaluated in a meta-analysis of 12 trials involving 863 patients [
         <a href="#rid54">
          54
         </a>
         ]. The following results were reported:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early administration of systemic glucocorticoids reduced admission rates (pooled odds ratio [OR] 0.40, 95% CI 0.21-0.78); eight patients (95% CI 5-21) would need to be treated to prevent one admission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit was more pronounced in those not receiving systemic glucocorticoids before ED presentation (OR 0.37, 95% CI 0.19-0.7) and in those with more severe asthma (OR 0.35, 95% CI 0.21-0.59).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral glucocorticoids were effective in reducing hospital admission (OR 0.24, 95% CI 0.11-0.53) compared with placebo in the three trials included in the meta-analysis that evaluated oral glucocorticoids in children with an acute asthma exacerbation.
        </p>
        <p>
        </p>
        <p>
         Another study examined outcomes before and after initiation of a medical directive that allowed triage nurse-initiated glucocorticoids before clinician assessment in 644 consecutive children presenting with a moderate-to-severe asthma exacerbation [
         <a href="#rid55">
          55
         </a>
         ]. Nursing initiation of glucocorticoids was associated with a reduced likelihood of admission (OR 0.56, 95% CI 0.36-0.87), as well as significantly decreased times to clinical improvement and discharge.
        </p>
        <p>
         A meta-analysis comparing a three- to five-day course of oral
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         (2 mg/kg/day for the first day and then 1 to 2 mg/kg/day for the subsequent two to four days) with
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         given as a single intramuscular dose (0.3 to 1.7 mg/kg) or one to two daily oral doses (0.6 mg/kg) for asthma exacerbations managed in the ED found that the treatments were equivalent with regard to rate of relapse, defined as an unplanned clinic visit, return ED visit, or unplanned hospitalization related to the initial asthma exacerbation [
         <a href="#rid56">
          56
         </a>
         ]. Similar results were seen in two subsequent randomized, open-label trials. The first of these compared a single oral dose of dexamethasone (0.3 mg/kg) to a three-day course of prednisolone (1 mg/kg/day), with equivalent Pediatric Respiratory Assessment Measure (PRAM) scores at day 4 after the ED visit [
         <a href="#rid57">
          57
         </a>
         ]. The second compared two daily oral doses of dexamethasone (0.6 mg/kg/dose, maximum dose 12 mg) to a five-day course of prednisone/prednisolone (1.5 mg/kg/day, maximum 60 mg, on day 1 and 1 mg/kg/day, maximum 60 mg, on days 2 through 5), with no difference seen in asthma symptoms and quality of life at day 7, admission rate, or unscheduled return visits to the ED [
         <a href="#rid58">
          58
         </a>
         ]. In the first trial and in the meta-analysis, lower rates of vomiting, both in the ED and at home, were seen in the groups treated with dexamethasone via either route of administration compared with prednisone/prednisolone [
         <a href="#rid56">
          56,57
         </a>
         ]. However, newer and more palatable prednisone/prednisolone liquid formulations and oral dissolving tablets are far better tolerated with less frequent episodes of emesis compared with older prednisone formulations.
        </p>
        <p>
         Most patients do not require delivery glucocorticoids via the intravenous route, even among those being hospitalized. However, for severely ill patients, intravenous access should be established, and intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         may be administered  (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H611715239">
         <span class="h3">
          Inhaled glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of inhaled glucocorticoids to treat children with acute asthma is an area of ongoing clinical research. Studies comparing the use of oral with inhaled glucocorticoids in the ED management of children with acute asthma have thus far had mixed results, although one systematic review found no differences between inhaled and systemic glucocorticoids [
         <a href="#rid59">
          59
         </a>
         ]. Until more conclusive data are available, we do
         <strong>
          not
         </strong>
         suggest the routine use of inhaled glucocorticoids in addition to, or instead of, systemic glucocorticoids in the management of acute asthma exacerbation in children.
        </p>
        <p>
         The following studies are illustrative:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some studies have found benefits of inhaled glucocorticoids compared with oral glucocorticoids (eg, earlier discharge from the ED, less vomiting, decreased relapse rate, improved clinical parameters, improved pulmonary function) [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other studies have found oral glucocorticoids and inhaled glucocorticoids to have similar outcomes [
         <a href="#rid62">
          62-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study found improved pulmonary function and a lower relapse rate with oral
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         compared with inhaled
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two randomized trials found no additional benefit to adding nebulized
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         to standard therapy (systemic glucocorticoids and inhaled
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         ) early in the course of treatment [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H933713928">
         <span class="h2">
          Nonstandard therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are insufficient data to support the routine administration of heliox,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , or leukotriene receptor antagonists (LTRAs) in the treatment of bronchospasm in children with acute asthma exacerbations.
        </p>
        <p class="headingAnchor" id="H2474698440">
         <span class="h3">
          Heliox
         </span>
         <span class="headingEndMark">
          —
         </span>
         In theory, a mixture of helium and oxygen may enhance beta-agonist delivery because the lower gas density should result in decreased flow resistance. The 2007 NAEPP guidelines suggest administration of beta-agonists with heliox in patients with life-threatening exacerbations or who are not responding to conventional therapy [
         <a href="#rid1">
          1
         </a>
         ]. However, the use of heliox should not delay intubation once it is considered necessary. Heliox is not used if the patient requires greater than 40 percent oxygen, because the beneficial effect of using a low-density gas is diminished as the oxygen fraction increases. (See
         <a class="medical medical_review" href="/z/d/html/541.html" rel="external">
          "Physiology and clinical use of heliox", section on 'Use in children'
         </a>
         and
         <a class="local">
          'Endotracheal intubation'
         </a>
         below.)
        </p>
        <p>
         The benefits of continuous beta-agonist administration delivery by heliox compared with oxygen were evaluated in a controlled trial in 30 children (2 to 18 years) with moderate-to-severe asthma (PIS ≥8)  (
         <a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid68">
          68
         </a>
         ]. After initial treatment with
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         inhalation and
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         , the patients were randomly assigned to receive continuous albuterol nebulization delivered by heliox or oxygen. At 240 minutes, patients in the heliox group had greater decrease in PIS from baseline (decrease of 7 versus 3 points). In addition, more patients in the heliox group were discharged from the hospital in less than 12 hours (73 versus 33 percent).
        </p>
        <p class="headingAnchor" id="H1823155329">
         <span class="h3">
          Ketamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to its bronchodilating properties, the dissociative agent
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         is the drug of choice to provide sedation and analgesia before intubating a child with asthma (see
         <a class="local">
          'Endotracheal intubation'
         </a>
         below). Although several small case series of nonintubated children treated with ketamine suggest that ketamine improves acute asthma [
         <a href="#rid69">
          69,70
         </a>
         ], the one randomized trial found that ketamine was no better than standard therapy in nonintubated children with severe acute asthma [
         <a href="#rid71">
          71,72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Sedation and paralysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2545098009">
         <span class="h3">
          Leukotriene receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The data do not support the routine use of LTRA therapy to treat children with acute asthma exacerbations requiring urgent or emergent care [
         <a href="#rid73">
          73
         </a>
         ]. LTRA add-on therapy in acute asthma has shown promise in adults [
         <a href="#rid74">
          74,75
         </a>
         ]. However, it does not appear to provide additional benefit in children when added to standard therapy for acute asthma [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">
          "Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Ineffective therapies'
         </a>
         .)
        </p>
        <p>
         A randomized trial of 117 children aged 5 to 15 years treated in the ED found no difference in the Modified Pulmonary Index Score (MPIS) between those treated with a single age-appropriate dose of
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         versus placebo [
         <a href="#rid76">
          76
         </a>
         ]. Intravenous montelukast was not effective in improving forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) in a randomized trial of children with acute asthma [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H668994448">
         <span class="h1">
          ADVICE RELATED TO COVID-19 PANDEMIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention (CDC) have identified asthma as a risk factor for severe coronavirus disease 2019 (COVID-19; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) [
         <a href="#rid78">
          78
         </a>
         ]. Expert groups have advised continuing usual ED management in patients with asthma [
         <a href="#rid79">
          79-82
         </a>
         ]. This includes following the usual guidelines for prompt initiation of systemic glucocorticoids for asthma exacerbations since delaying therapy is known to increase the risk of a life-threatening exacerbation. One exception to routine care is that use of nebulized medications should be minimized, if possible, because of the risk of aerosolizing SARS-CoV-2 resulting in nosocomial infection. For most children, clinicians should initiate metered-dose inhaler with spacer (MDI-S) therapy and only switch to nebulized beta-agonist therapy if the child is moderately or severely ill and has poor response to MDI-S therapy. If nebulized therapy or noninvasive ventilation is employed, all health care workers should wear full personal protective equipment, including an N-95 mask or respirator, eye protection, gloves, and a gown. In addition, clinicians should have a low threshold for testing for COVID-19 in all children with an acute asthma exacerbation; any such child with fever should be tested. (See
         <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">
          "COVID-19: Clinical manifestations and diagnosis in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3007540828">
         <span class="h1">
          INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is based upon the initial assessment of severity  (
         <a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">
          table 2
         </a>
         ) followed by ongoing monitoring of response to therapy  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ). All drug doses and routes are shown in the tables  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Assessment of severity'
         </a>
         above and
         <a class="local">
          'Monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Mild exacerbation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with a mild asthma exacerbation (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         inhalation therapy via small-volume nebulizer (SVN) or metered-dose inhaler with spacer (MDI-S). If repeated doses are needed, they should be given up to every 20 minutes for three doses [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Inhaled short-acting beta-2 agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give systemic glucocorticoids (eg, oral
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         ) to those who fail to show sustained improvement or worsen after one inhalation therapy or who have a history of severe or recurrent exacerbations in the past. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Moderate exacerbation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with a moderate asthma exacerbation (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the following therapies are administered  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         bromide up to every 20 minutes for three doses or continuously for one hour. (See
         <a class="local">
          'Inhaled short-acting beta-2 agonists'
         </a>
         above and
         <a class="local">
          'Ipratropium bromide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic glucocorticoids (oral administration of
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         is suitable for most patients) within 30 to 60 minutes after arrival in the ED in a manner that does not delay the initiation of beta-agonist therapy. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Severe exacerbation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with a severe asthma exacerbation (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         , as noted above for moderate exacerbation, for the first hour. Most children with a severe exacerbation will need ongoing administration of continuous rather than intermittent nebulized albuterol, unless they experience dramatic improvement after their first hour of albuterol therapy. (See
         <a class="local">
          'Moderate exacerbation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with very poor inspiratory flow or severely ill children who cannot cooperate with nebulized therapy can be treated with
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         administered intramuscularly or subcutaneously instead of inhaled
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         . The intramuscular route has the theoretical advantage of more rapid distribution, and, unlike epinephrine, terbutaline is a beta-selective agent. (See
         <a class="local">
          'Inhaled short-acting beta-2 agonists'
         </a>
         above and
         <a class="local">
          'Ipratropium bromide'
         </a>
         above and
         <a class="local">
          'Parenteral beta-agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         , which can be started as soon as intravenous access is obtained. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         . (See
         <a class="local">
          'Magnesium sulfate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4195854276">
         <span class="h3">
          Impending respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pediatric intensive care unit (PICU) and/or anesthesia should be consulted when a patient has signs of impending respiratory failure  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ), including cyanosis, inability to maintain respiratory effort (respiratory rate may be inappropriately normal to low), depressed mental status (lethargy or agitation), pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) &lt;90 percent, and/or respiratory acidosis (elevated partial pressure of carbon dioxide [pCO
         <sub>
          2
         </sub>
         ] noted on venous, arterial, or capillary blood gas sample). Intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         in addition to inhaled short-acting beta-2 agonists (SABAs) and noninvasive positive pressure ventilation (NPPV) or endotracheal intubation may be indicated for these children. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         and
         <a class="local">
          'Noninvasive positive pressure ventilation'
         </a>
         below and
         <a class="local">
          'Endotracheal intubation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1035850600">
         <span class="h4">
          Intravenous terbutaline
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the child with impending respiratory failure, the risk-benefit ratio favors the use of intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         in addition to continuously nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Parenteral beta-agonists'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2676526769">
         <span class="h4">
          Noninvasive positive pressure ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         NPPV (continuous positive airway pressure [CPAP] or bilevel positive airway support [BPAP]) is sometimes used to treat severely ill children with asthma who are responding poorly to other interventions, although there are little data proving the efficacy of this approach [
         <a href="#rid83">
          83
         </a>
         ]. This strategy of employing positive pressure has the theoretical benefit of decreasing the workload of fatigued muscles by decreasing the pressure needed to initiate a breath and helping to prevent airway collapse on exhalation. Subsets of patients, as yet hard to define, do have demonstrable benefit from the use of NPPV. As such, it is reasonable for clinicians to employ this option in children with severe exacerbations refractory to other interventions, with the caveat that NPPV should be discontinued if there is clinical deterioration. NPPV is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">
          "Noninvasive ventilation for acute and impending respiratory failure in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126295.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Practical aspects of initiation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3236578804">
         <span class="h4">
          Endotracheal intubation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intubation should be approached cautiously in patients with status asthmaticus because manipulation of the airway can cause increased airflow obstruction due to exaggerated bronchial responsiveness. Clinicians must be prepared to manage acute deterioration after intubation. Adequate venous access, noninvasive monitoring, and sedation should be optimized before intubation. The clinician most experienced with airway management should perform the intubation. The indications for endotracheal intubation in children with asthma and the performance of the procedure are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">
          "Technique of emergency endotracheal intubation in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Endotracheal intubation and mechanical ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2041854226">
         <span class="h1">
          FURTHER EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1658657861">
         <span class="h2">
          Indications for chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with asthma exacerbations do not require chest radiographs (CXRs), since they rarely provide information that alters the management of children with acute asthma exacerbation [
         <a href="#rid84">
          84,85
         </a>
         ]. Indications for CXR to rule out pneumonia, atelectasis, and air leak include fever (&gt;39ºC); presence of focal examination findings (eg, persistent crackles or decreased breath sounds, crepitus); persistent tachypnea, hypoxemia, or chest pain; severe disease; or uncertainty about the diagnosis [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5752.html" rel="external">
          "Evaluation of wheezing in infants and children", section on 'Radiography'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1648628047">
         <span class="h2">
          Alternative diagnoses and comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who present with acute onset of wheezing and do not respond to the usual asthma therapies should be evaluated for alternative diagnoses and comorbidities  (
         <a class="graphic graphic_table graphicRef67370" href="/z/d/graphic/67370.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef62889" href="/z/d/graphic/62889.html" rel="external">
          table 7
         </a>
         ). In addition to asthma, acute onset of wheezing in a child is most often caused by an infectious process (particularly viral bronchiolitis in infants less than two years of age and atypical pneumonia in older children) or foreign body aspiration (FBA). Environmental allergies and obesity are among the more common comorbidities. Common triggers and comorbidities are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5752.html" rel="external">
          "Evaluation of wheezing in infants and children", section on 'Acute wheezing (hours to days)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management", section on 'Controlling asthma triggers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3315967219">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing monitoring of respiratory rate, heart rate, oxygen saturation, degree of alertness, accessory muscle use, and retractions is crucial to decisions regarding treatment and disposition [
         <a href="#rid86">
          86
         </a>
         ]. The frequency of monitoring varies depending upon the severity of illness and response to initial therapy but for most patients is typically every 20 to 30 minutes for the first hour of therapy. Patients who require continuous nebulizer therapy continue to be monitored every 20 to 30 minutes. Clinicians may also find it helpful to measure peak expiratory flow rate (PEFR) in select patients (eg, a person with obesity, in whom assessment of aeration is more difficult). However, assessment of PEFR may have limited utility in the assessment of sicker or younger children. It is optimal if the child can make three attempts while standing (the best score is used), and it is most useful when it can be compared with the child's known personal best score. (See
         <a class="medical medical_review" href="/z/d/html/5735.html" rel="external">
          "Overview of pulmonary function testing in children", section on 'Peak expiratory flow rate'
         </a>
         .)
        </p>
        <p>
         Management decisions can be based upon the physical exam findings, along with oxyhemoglobin saturation assessed with pulse oximetry. In addition, an elevated end tidal CO
         <sub>
          2
         </sub>
         measurement assessed noninvasively via capnometry may indicate impending respiratory failure. It is rarely necessary to obtain arterial blood gas (ABG) samples in children with acute asthma. ABGs obtained before aggressive intervention are often abnormal (hypercapnia) in moderately or severely ill children but rarely affect management and usually improve after therapy. In children who require admission to the intensive care unit (ICU), measurement of partial pressure of carbon dioxide (pCO
         <sub>
          2
         </sub>
         ) via ABG after a clinical plateau has been reached provides an objective measure of disease severity. Data suggest that capillary blood is an acceptable sample alternative to arterial blood if only acid-base parameters (pH and
         <em>
          p
         </em>
         CO
         <sub>
          2
         </sub>
         ) are of clinical interest [
         <a href="#rid87">
          87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H428391272">
         <span class="h1">
          SUBSEQUENT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subsequent management depends upon response to initial therapy  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ). All drug doses and routes are shown in the tables  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ). Discharge criteria for patients who do respond to therapy are reviewed below. (See
         <a class="local">
          'Assessment of severity'
         </a>
         above and
         <a class="local">
          'Discharge to home'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3087339197">
         <span class="h2">
          Poor response and severely ill
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a poor response to initial treatment
         <strong>
          and
         </strong>
         severe signs and/or symptoms (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the following additional steps are taken while awaiting admission to the hospital (see
         <a class="local">
          'Hospitalization'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consult the pediatric intensive care unit (PICU) and/or anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give continuously nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (or give intermittently every 30 to 45 minutes) without
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Inhaled short-acting beta-2 agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         if not already given and there is lack of clinical improvement or clinical deterioration despite treatment with
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         bromide, and systemic glucocorticoids. (See
         <a class="local">
          'Magnesium sulfate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who do not respond to these interventions and have signs and/or symptoms of impending respiratory failure, administer intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         after completion of the
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         infusion. Dosing for intravenous terbutaline in the ED setting is as follows: 10 microgram/kg bolus over 10 minutes, followed by 0.3 to 0.5 microgram/kg/minute; every 30 minutes the infusion may be increased by 0.5 microgram/kg/minute to a maximum of 3 microgram/kg/minute. (Higher doses are sometimes used in the ICU setting.) (See
         <a class="local">
          'Parenteral beta-agonists'
         </a>
         above and
         <a class="local">
          'Impending respiratory failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess for alternative diagnoses or comorbidities. (See
         <a class="local">
          'Alternative diagnoses and comorbidities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional management may include noninvasive positive pressure ventilation (NPPV) or endotracheal intubation. (See
         <a class="local">
          'Noninvasive positive pressure ventilation'
         </a>
         above and
         <a class="local">
          'Endotracheal intubation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2969760816">
         <span class="h2">
          Incomplete response and moderately ill
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an incomplete response to initial treatment
         <strong>
          and
         </strong>
         continued moderate signs and/or symptoms (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         continuously (or every 30 to 45 minutes).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         if it was not already given and symptoms are moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reassess response to therapy in one to three hours to determine whether to admit or discharge to home. (See
         <a class="local">
          'Disposition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2371104267">
         <span class="h2">
          Incomplete response and mildly ill
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an incomplete response to initial treatment
         <strong>
          and
         </strong>
         continued mild signs and/or symptoms (see
         <a class="local">
          'Assessment of severity'
         </a>
         above), the approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give nebulized
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         every 30 to 45 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reassess response to therapy in one to three hours to determine whether to admit or discharge to home. (See
         <a class="local">
          'Disposition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276287008">
         <span class="h2">
          Good response and minimal to no symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have resolution of symptoms or marked improvement and the patient and parents/caregivers have a good understanding of asthma management and are able to adhere to therapy can be discharged to home  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Discharge to home'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2542933380">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision regarding disposition (eg, discharge to home, continued observation, or hospitalization) is based upon both clinical and social factors.
        </p>
        <p class="headingAnchor" id="H2745822411">
         <span class="h2">
          Hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who were moderately to severely ill on arrival and who have little improvement or worsen after initial therapy with beta-agonists and systemic glucocorticoids require hospitalization. This includes patients who continue to have significant wheezing and retracting and poor aeration.
        </p>
        <p>
         Additional factors that suggest a need for hospitalization include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta-agonist therapy more often than four hours; patients who require treatment more often than every two hours may need to be admitted to an intensive care unit (ICU; this varies from institution to institution and is dependent upon the level of care that can be administered in the regular inpatient unit)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Requirement for supplemental oxygen/low oxygen saturation on pulse oximetry an hour or more after commencement of initial therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to self-hydrate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of rapid progression of severity in past exacerbations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor adherence with outpatient medication regimen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent treatment with systemic glucocorticoids (includes current treatment with oral glucocorticoids at the time of presentation) or beta-agonist overuse
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate access to medical care, including lack of transportation back to the hospital if deterioration occurs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor social support system at home, with inability of the caregiver(s) to provide medical care and supervision at home
        </p>
        <p>
        </p>
        <p>
         Severely ill children with a poor response to ED interventions will require admission to a pediatric intensive care unit (PICU). Clinicians should have a low threshold to admit a child with altered mental status (may present as drowsiness or agitation) to an ICU. Other factors that may influence this decision include a history of severe exacerbations and/or a prior need for ICU management [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
         Inpatient and ICU therapy for acute asthma exacerbations in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3994349623">
         <span class="h2">
          Discharge to home
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who have marked improvement in clinical parameters within the first one to two hours of therapy may be discharged home [
         <a href="#rid1">
          1
         </a>
         ]. Marked improvement is manifested by diminished or absent wheezing and retracting and increased aeration that is sustained at least 60 minutes after the most recent
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         dose.
        </p>
        <p class="headingAnchor" id="H3544536955">
         <span class="h3">
          Discharge medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients seen for an acute asthma exacerbation should have an inhaled short-acting beta-2 agonist (SABA; eg,
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         ) available for treatment of symptoms [
         <a href="#rid1">
          1
         </a>
         ]. We suggest treatment with a SABA (eg, albuterol) every four hours during waking hours and up to every four hours as needed during sleep for the first three days after an ED visit for an asthma exacerbation. After that, albuterol dosing should be weaned as tolerated, with the goal of discontinuing by day 5 to 7. (See
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms", section on 'Short-acting beta agonists (SABAs)'
         </a>
         .)
        </p>
        <p>
         We treat children with a short course of oral glucocorticoids if they received a dose of systemic glucocorticoids in the ED. A meta-analysis of combined adult and pediatric data found that this treatment was associated with fewer relapses to additional care, a decreased number of subsequent hospitalizations, and less
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         use [
         <a href="#rid89">
          89
         </a>
         ]. As few as 10 patients need to be treated with systemic glucocorticoids to prevent relapse. A one- to two day course of
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         given once per day has become the glucocorticoid of choice for post-ED asthma management [
         <a href="#rid56">
          56
         </a>
         ]. It is well-tolerated and has the same efficacy as a five-day course of
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         given twice each day. More prolonged glucocorticoid regimens may be indicated for those with persistent symptoms or those whose control regimen includes oral glucocorticoids. Glucocorticoids that are administered for less than 10 days do not require a taper at discontinuation [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Whether inhaled glucocorticoids offer any short-term benefits in addition to inhaled
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         and oral glucocorticoids when started in the ED or at the time of discharge from the ED in patients who were not already receiving inhaled glucocorticoids as controller therapy is a question that remains unanswered [
         <a href="#rid91">
          91,92
         </a>
         ]. However, patients may be started on an inhaled glucocorticoid in the ED, if controller therapy is indicated, to ensure that institution of this therapy is not delayed or forgotten [
         <a href="#rid93">
          93
         </a>
         ]. Alternatively, the treating clinician in the ED can advise the parents/caregivers to address this issue during the follow-up visit with the child's primary care provider. (See
         <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">
          "Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"
         </a>
         .)
        </p>
        <p>
         Benefits were not seen with leukotriene receptor antagonists (LTRAs) as monotherapy in children discharged from the ED after treatment for acute asthma was successful. A five-day course of
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         was not as effective as a similar course of
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         in a randomized trial of 130 children with mild-to-moderate acute asthma exacerbations who were stabilized with prednisolone in the ED [
         <a href="#rid94">
          94
         </a>
         ]. Treatment failure occurred in 8 percent of children treated with prednisolone compared with 22 percent treated with montelukast.
        </p>
        <p class="headingAnchor" id="H2009477857">
         <span class="h3">
          Discharge education
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to discharge from the ED, it is recommended that the following are reviewed with patients and their parents/caregivers [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs and symptoms necessitating a return visit to the ED including worsening shortness of breath, difficulty speaking a complete sentence, or increased work of breathing
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The need to follow-up with their primary care provider or asthma specialist within one week of the ED visit
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discharge medications, with respect to purpose, side effects, and proper technique for administration (see
         <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">
          "Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'Spacer devices'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'Valved-holding chambers'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A written asthma action plan  (
         <a class="graphic graphic_form graphicRef71958 graphicRef55900" href="/z/d/graphic/71958.html" rel="external">
          form 1A-B
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/566.html" rel="external">
          "Asthma education and self-management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk factors for asthma (see
         <a class="medical medical_review" href="/z/d/html/572.html" rel="external">
          "Risk factors for asthma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of acute exacerbations (see
         <a class="medical medical_review" href="/z/d/html/562.html" rel="external">
          "Trigger control to enhance asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/530.html" rel="external">
          "Allergen avoidance in the treatment of asthma and allergic rhinitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2782446003">
         <span class="h3">
          Follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients discharged from the ED should follow up with their primary care provider or asthma specialist within one week of the ED visit [
         <a href="#rid1">
          1
         </a>
         ]. At the follow-up visit, the primary care provider can review the child's asthma control, asthma care plan, and initiate or alter controller therapy as indicated. (See
         <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">
          "Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3442167100">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113453.html" rel="external">
          "Society guideline links: Asthma in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16116.html" rel="external">
          "Patient education: How to use your child's dry powder inhaler (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15344.html" rel="external">
          "Patient education: Asthma in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16115.html" rel="external">
          "Patient education: How to use your child's metered dose inhaler (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1173.html" rel="external">
          "Patient education: Asthma inhaler techniques in children (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1172.html" rel="external">
          "Patient education: Asthma treatment in children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H43">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Determining exacerbation severity
         </strong>
         – The severity of an asthma exacerbation is primarily determined by assessment of clinical findings, occasionally supplemented by objective tests  (
         <a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">
          table 1
         </a>
         ). The initial severity of the exacerbation and level of treatment needed can also be determined using an asthma exacerbation severity score such as the pulmonary index score (PIS)  (
         <a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">
          table 2
         </a>
         ) or the Pediatric Respiratory Assessment Measure (PRAM)  (
         <a class="graphic graphic_table graphicRef91731" href="/z/d/graphic/91731.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Assessment of severity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Assessment of exacerbation severity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild
         </strong>
         – A mild exacerbation is characterized by normal alertness, slight tachypnea, expiratory wheezing only, a mildly prolonged expiratory phase, minimal accessory muscle use, and an oxygen saturation of &gt;95 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate
         </strong>
         – A moderate exacerbation is defined as normal alertness, tachypnea, wheezing throughout expiration with or without inspiratory wheezing, an inspiratory-expiratory ratio of approximately 1:2, significant use of accessory muscles, and an oxygen saturation that is typically 92 to 95 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe
         </strong>
         – A severe exacerbation is defined as lethargy or agitation, inability to repeat a short phrase, extreme tachypnea, inspiratory and expiratory wheezing, an inspiratory-expiratory ratio exceeding 1:2, very poor aeration, significant use of accessory muscles, and an oxygen saturation that is typically &lt;92 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – The approach to the initial management of the child who presents to the emergency department (ED) with an asthma exacerbation is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ) and as follows, with dosing and route of administration summarized in the tables  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 5
         </a>
         ) (see
         <a class="local">
          'Initial treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with hypoxemia
         </strong>
         – Administration of supplemental oxygen is indicated if oxygen saturation is ≤92 percent in room air. (See
         <a class="local">
          'Management of hypoxemia and hypercapnia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          All patients
         </strong>
         – All patients seen in the ED for an acute asthma exacerbation require treatment with an inhaled short-acting beta-2 agonist (SABA or beta-agonist), such as
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (salbutamol) or an equivalent. Albuterol is administered by nebulizer or metered-dose inhaler with a valved holding chamber (preferred) or spacer (MDI-VHC/S) up to every 20 minutes for one to three doses or continuously via nebulizer. The delivery method and dose vary with the severity of the attack, and studies show similar outcomes with each mode of delivery. Subcutaneous or intramuscular administration of a beta-agonist (eg,
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         ) is an alternative for children with poor inspiratory flow and/or who have moderate-to-severe symptoms and are uncooperative with inhalation therapy. (See
         <a class="local">
          'Inhaled short-acting beta-2 agonists'
         </a>
         above and
         <a class="local">
          'Parenteral beta-agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with mild exacerbations
         </strong>
         – We suggest oral glucocorticoids for children who present to the ED with a mild asthma exacerbation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), although it is reasonable to omit this therapy in children who have not received beta-agonist therapy within a few hours of presenting for medical care and who respond promptly to a single
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         treatment in the ED. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with moderate-to-severe exacerbations
         </strong>
         –
         <strong>
         </strong>
         For patients who present to the ED with a moderate-to-severe asthma exacerbation:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We recommend systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Systemic glucocorticoids should be administered within 30 to 60 minutes after arrival in the ED. Oral agents (eg,
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         ) are preferred in those with moderate exacerbations. Dexamethasone is preferred because of its prolonged half-life, which allows for shorter dosing, and similar efficacy compared with prednisone and prednisolone. We administer systemic glucocorticoids intravenously in most patients with severe exacerbations since they are likely to require additional intravenous medications. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We recommend inhaled
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         bromide (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We administer ipratropium bromide combined with initial beta-agonist therapy (given as nebulizer treatments up to every 20 minutes for three doses or continuously); alternatively, it may be administered with the second and third treatments. (See
         <a class="local">
          'Ipratropium bromide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         as part of the initial therapy only in patients with a severe exacerbation (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with impending respiratory failure
         </strong>
         – The pediatric intensive care unit (PICU) and/or anesthesia should be consulted when a patient has signs and/or symptoms of impending respiratory failure. (See
         <a class="local">
          'Impending respiratory failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Further evaluation in patients who are not responding to usual therapy
         </strong>
         – Most children with asthma exacerbations do not require chest radiographs (CXRs) as part of their evaluation. Patients who present with acute onset of wheezing and do not respond to the usual asthma therapies should be evaluated for alternative diagnoses and comorbidities  (
         <a class="graphic graphic_table graphicRef67370" href="/z/d/graphic/67370.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef62889" href="/z/d/graphic/62889.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Further evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent management and disposition
         </strong>
         – The disposition of children with acute asthma exacerbation depends upon the response during the first one to two hours of therapy and subsequent severity of symptoms  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Subsequent management'
         </a>
         above and
         <a class="local">
          'Disposition'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Marked improvement
         </strong>
         – Children who have marked improvement in clinical parameters may be discharged home. All patients seen for an acute asthma exacerbation should have an inhaled SABA (eg,
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         ) available for treatment of symptoms. We typically advise treating with albuterol every four hours for the first three days after discharge from the ED; albuterol frequency may be weaned for the next two to three days following that, as tolerated. We treat children with a short course of oral glucocorticoids if they received a dose of systemic glucocorticoids in the ED. Patients discharged from the ED should follow-up with their primary care provider or asthma specialist within one week after the ED visit. (See
         <a class="local">
          'Good response and minimal to no symptoms'
         </a>
         above and
         <a class="local">
          'Discharge to home'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Poor or incomplete response
         </strong>
         – Children with no or incomplete improvement within the first two hours of therapy require continued observation and treatment  (
         <a class="graphic graphic_algorithm graphicRef123081" href="/z/d/graphic/123081.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Incomplete response and mildly ill'
         </a>
         above and
         <a class="local">
          'Incomplete response and moderately ill'
         </a>
         above and
         <a class="local">
          'Poor response and severely ill'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inhaled SABA is continued in all patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest the administration of intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         for patients who have a poor response to initial treatment with beta-agonist,
         <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">
          ipratropium
         </a>
         , and systemic glucocorticoids and have moderate-to-severe symptoms (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ). (See
         <a class="local">
          'Magnesium sulfate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest administration of intravenous
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         if there is no response to intravenous
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         and the patient has signs and/or symptoms of impending respiratory failure (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Parenteral beta-agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients who continue to have symptoms and/or continued need for supplemental oxygen after treatment with bronchodilators and systemic glucocorticoids require hospitalization. Severely ill children with a poor response to ED interventions require admission to a PICU. (See
         <a class="local">
          'Hospitalization'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma.(NIH publication no. 08-4051). Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124:1312.
          </a>
         </li>
         <li class="breakAll">
          Global Initiative for Asthma. 2019 GINA Report: Global Strategy for Asthma Management and Prevention. https://ginasthma.org/gina-reports/ (Accessed on January 21, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker AB, Nelson NA, Simons FE. Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. J Pediatr 1983; 102:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turpeinen M, Kuokkanen J, Backman A. Adrenaline and nebulized salbutamol in acute asthma. Arch Dis Child 1984; 59:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson M, Bulloch B, Garcia-Filion P, Keahey L. Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. J Asthma 2011; 48:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ralston ME, Euwema MS, Knecht KR, et al. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005; 29:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004; 145:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ploin D, Chapuis FR, Stamm D, et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial. Pediatrics 2000; 106:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013; :CD000052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubilar L, Castro-Rodriguez JA, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol 2000; 29:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996; 3:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besbes-Ouanes L, Nouira S, Elatrous S, et al. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med 2000; 36:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clay MM, Pavia D, Newman SP, et al. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; 2:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood JA, Wilson RS, Bray C. Changes in salbutamol concentration in the reservoir solution of a jet nebulizer. Br J Dis Chest 1986; 80:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983; 38:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas JG, Leslie MJ, Crompton GK, Grant IW. Is the flow rate used to drive a jet nebuliser clinically important? Br Med J (Clin Res Ed) 1985; 290:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J Physiol 1987; 253:C97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics 1999; 103:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995; 126:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2013; :CD000060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med 2000; 36:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000; :CD001490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005; 90:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shan Z, Rong Y, Yang W, et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med 2013; 107:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths B, Kew KM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database Syst Rev 2016; 4:CD011050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su Z, Li R, Gai Z. Intravenous and Nebulized Magnesium Sulfate for Treating Acute Asthma in Children: A Systematic Review and Meta-Analysis. Pediatr Emerg Care 2018; 34:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruikkonen H, Tapiainen T, Kallio M, et al. Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knightly R, Milan SJ, Hughes R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2017; 11:CD003898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012; 12:CD010179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogie AL, Towne D, Luckett PM, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care 2007; 23:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansur AH, Afridi L, Sullivan J, et al. Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety. J Asthma 2014; 51:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doymaz S, Schneider J. Safety of Terbutaline for Treatment of Acute Severe Pediatric Asthma. Pediatr Emerg Care 2018; 34:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LEVIN SJ. The management of the acute attack of asthma in childhood; special reference to short-term steroid therapy. AMA J Dis Child 1959; 97:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics 1990; 86:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Rodriguez JA, Beckhaus AA, Forno E. Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis. Pediatr Pulmonol 2016; 51:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnett PL, Caputo GL, Baskin M, Kuppermann N. Intravenous versus oral corticosteroids in the management of acute asthma in children. Ann Emerg Med 1997; 29:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkland SW, Cross E, Campbell S, et al. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Cochrane Database Syst Rev 2018; 6:CD012629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. Cochrane Database Syst Rev 2016; :CD011801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon S, Tompkins T, Dayan PS. Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma. Pediatr Emerg Care 2007; 23:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klig JE, Hodge D 3rd, Rutherford MW. Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone. J Asthma 1997; 34:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 2000; 136:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; :CD002178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zemek R, Plint A, Osmond MH, et al. Triage nurse initiation of corticosteroids in pediatric asthma is associated with improved emergency department efficiency. Pediatrics 2012; 129:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics 2014; 133:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin JJ, McCoy S, Kennedy U, et al. A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department. Ann Emerg Med 2016; 67:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paniagua N, Lopez R, Muñoz N, et al. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. J Pediatr 2017; 191:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckhaus AA, Riutort MC, Castro-Rodriguez JA. Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review. Pediatr Pulmonol 2014; 49:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarfone RJ, Loiselle JM, Wiley JF 2nd, et al. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med 1995; 26:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999; 88:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manjra AI, Price J, Lenney W, et al. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med 2000; 94:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999; 88:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998; 102:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006; 118:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upham BD, Mollen CJ, Scarfone RJ, et al. Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial. Acad Emerg Med 2011; 18:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alangari AA, Malhis N, Mubasher M, et al. Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: a double-blind, randomized, controlled trial. Chest 2014; 145:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics 2005; 116:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrillo TM, Fortenberry JD, Linzer JF, Simon HK. Emergency department use of ketamine in pediatric status asthmaticus. J Asthma 2001; 38:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JY, Macias CG. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med 2005; 46:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jat KR, Chawla D. Ketamine for management of acute exacerbations of asthma in children. Cochrane Database Syst Rev 2012; 11:CD009293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 2012; :CD006100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Arch Dis Child 2010; 95:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris CR, Becker AB, Piñieiro A, et al. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol 2010; 104:161.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (Accessed on November 01, 2022).
         </li>
         <li class="breakAll">
          https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/.
         </li>
         <li class="breakAll">
          https://college.acaai.org/acaai-statement-covid-19-and-asthma-allergy-and-immune-deficiency-patients-3-12-20.
         </li>
         <li class="breakAll">
          https://education.aaaai.org/sites/default/files/COVID19_US%20FINAL.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrams EM, Szefler SJ. Managing Asthma during Coronavirus Disease-2019: An Example for Other Chronic Conditions in Children and Adolescents. J Pediatr 2020; 222:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korang SK, Feinberg J, Wetterslev J, Jakobsen JC. Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database Syst Rev 2016; 9:CD012067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershel JC, Goldman HS, Stein RE, et al. The usefulness of chest radiographs in first asthma attacks. N Engl J Med 1983; 309:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinonez RA, Garber MD, Schroeder AR, et al. Choosing wisely in pediatric hospital medicine: five opportunities for improved healthcare value. J Hosp Med 2013; 8:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canny GJ, Reisman J, Healy R, et al. Acute asthma: observations regarding the management of a pediatric emergency room. Pediatrics 1989; 83:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escalante-Kanashiro R, Tantaleán-Da-Fieno J. Capillary blood gases in a pediatric intensive care unit. Crit Care Med 2000; 28:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll CL, Schramm CM, Zucker AR. Severe exacerbations in children with mild asthma: characterizing a pediatric phenotype. J Asthma 2008; 45:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007; :CD000195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993; 341:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmonds ML, Camargo CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2000; :CD002308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmonds ML, Camargo CA, Saunders LD, et al. Inhaled steroids in acute asthma following emergency department discharge. Cochrane Database Syst Rev 2000; :CD002316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarfone RJ, Zorc JJ, Angsuco CJ. Emergency physicians' prescribing of asthma controller medications. Pediatrics 2006; 117:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuh S, Willan AR, Stephens D, et al. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. J Pediatr 2009; 155:795.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5740 Version 56.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma.(NIH publication no. 08-4051). Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8414819" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14555560" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14555560" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6827423" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6465938" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adrenaline and nebulized salbutamol in acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21275850" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16027572" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15961004" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15988423" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289762" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10920157" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24037768" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738013" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239105" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239106" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Continuous versus intermittent albuterol nebulization in the treatment of acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8922008" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Continuous vs intermittent nebulized albuterol for emergency management of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969220" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583926" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Continuous versus intermittent beta-agonists in the treatment of acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8403956" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2927990" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6136746" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Assessment of jet nebulisers for lung aerosol therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3730263" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Changes in salbutamol concentration in the reservoir solution of a jet nebulizer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6648854" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Factors influencing the size distribution of aerosols from jet nebulisers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2856895" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Is the flow rate used to drive a jet nebuliser clinically important?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3605331" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10103297" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ipratropium bromide added to asthma treatment in the pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9761804" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7699549" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055613" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23966133" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969218" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796650" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Magnesium sulfate for treating exacerbations of acute asthma in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613519" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A meta-analysis on intravenous magnesium sulphate for treating acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23290189" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27126744" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intravenous magnesium sulfate for treating children with acute asthma in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29851914" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intravenous and Nebulized Magnesium Sulfate for Treating Acute Asthma in Children: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437941" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29182799" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Inhaled magnesium sulfate in the treatment of acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235685" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024371" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomised trial of intravenous salbutamol in early management of acute severe asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17572517" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25019350" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26959519" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Safety of Terbutaline for Treatment of Acute Severe Pediatric Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13636698" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The management of the acute attack of asthma in childhood; special reference to short-term steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2201941" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27074244" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9018184" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intravenous versus oral corticosteroids in the management of acute asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29859017" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27176676" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Different oral corticosteroid regimens for acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17726409" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9350159" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10700684" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279756" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Early emergency department treatment of acute asthma with systemic corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22430452" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Triage nurse initiation of corticosteroids in pediatric asthma is associated with improved emergency department efficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24515516" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dexamethasone for acute asthma exacerbations in children: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26460983" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29173304" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23929666" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7574132" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10503681" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11192957" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10503682" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802368" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882819" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21762229" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24384609" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: a double-blind, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263999" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567251" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Ketamine to avoid mechanical ventilation in severe pediatric asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11758894" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Emergency department use of ketamine in pediatric status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15988425" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23152273" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Ketamine for management of acute exacerbations of asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592708" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12456380" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A randomized controlled trial of intravenous montelukast in acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15539716" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20522464" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306820" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306820" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306820" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306820" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306820" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32330469" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Managing Asthma during Coronavirus Disease-2019: An Example for Other Chronic Conditions in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27687114" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Non-invasive positive pressure ventilation for acute asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6866069" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The usefulness of chest radiographs in first asthma attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23955837" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Choosing wisely in pediatric hospital medicine: five opportunities for improved healthcare value.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2927989" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Acute asthma: observations regarding the management of a pediatric emergency room.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10667527" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Capillary blood gases in a pediatric intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18612906" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Severe exacerbations in children with mild asthma: characterizing a pediatric phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636617" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Corticosteroids for preventing relapse following acute exacerbations of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8094111" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Double-blind trial of steroid tapering in acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908552" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Early use of inhaled corticosteroids in the emergency department treatment of acute asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908556" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Inhaled steroids in acute asthma following emergency department discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16510663" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Emergency physicians' prescribing of asthma controller medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19656525" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
